IL7R and acute lymphoblastic leukemia: It is also possible that blocking pathways that were reported to interfere with T-ALL progression using small molecule inhibitors, such as ones targeting JAK/STAT signaling pathways, may also synergize well with anti IL-7Rα mAb treatments (249).